Prostate and Breast Cancer Cured by HIFU?
If you have prostate or breast cancer there is now a possible cure with a relatively new procedure. Although it is not permitted in the USA or UK at the time of this writing the UK is looking at it closely in regard to prostate cancer and changes my be coming for them. You may be eligible for this procedure if it has not metastasized yet. It is available in Canada, Mexico and China, France.
Below you will find the information and links that will help you to make a decision and lead you to a physician that does this procedure.
And here are more informative detailed videos. They will explain the risks and how to monitor and manage reinsurance.
Here are other more detailed videos to watch:
and how to monitor your status after the procedure:
Do a search at PubMed for Dr. F. Wu and HIFU
Dissolving Prostate Cancer
According to Dr. Robertson, HIFU is like an ultrasound machine used on pregnant women except it creates sound waves that are much more powerful and focused. A probe sends ultrasound waves through a patient’s rectal wall. The waves are so hot and intense, they actually kill cancer cells.
“It is possible to exactly target where one wants to give heat,” says Dr. Robertson.
Kielar says he could relate to the sound waves used by HIFU. “I took the ultra sound wave from the company and basically kept dividing by two,” says Kielar. “I brought it down to the audible frequency range, and I determined it was an F sharp.”
Although HIFU is a non-invasive treatment for prostate cancer, it can cause sexual dysfunction, and some men may experience incontinence. It is widely used in Europe but is still in clinical trials in the U.S. The latest studies show that 80 percent of men remained cancer-free seven years after treatment. For Kielar, HIFU proved to be a painless success.
HIFU found in Canada: www.hifu.ca/
The Race for the Cure has been won in China
Wu, F., Z. B. Wang, et al. (2003)“A randomised clinical trial of high-intensity focused ultrasound ablation for the treatment of patients with localised breast cancer.” Br J Cancer 89(12): 2227-33.
High-intensity focused ultrasound (HIFU) is a noninvasive treatment that induces complete coagulative necrosis of a tumour at depth through the intact skin. This study was to explore the possibility of using HIFU for the treatment of patients with localised breast cancer in a controlled clinical trial. A total of 48 women with biopsy-proven breast cancer (T(1-2), N(0-2), M0) were randomised to the control group in which modified radical mastectomy was performed, and the HIFU group in which an extracorporeal HIFU ablation of breast cancer was followed by modified radical mastectomy. Short-term follow-up, pathologic and immunohistochemical stains were performed to assess the therapeutic effects on tumour and complications of HIFU. The results showed that no severe side effect was observed in the HIFU-treated patients. Pathologic findings revealed that HIFU-treated tumour cells underwent complete coagulative necrosis, and tumour vascular vessels were severely damaged. Immunohistochemical staining showed that no expression of PCNA, MMP-9, and CD44v6 was detected within the treated tumour cells in the HIFU group, indicating that the treated tumour cells lost the abilities of proliferation, invasion, and metastasis. It is concluded that, as a noninvasive therapy, HIFU could be effective, safe, and feasible in the extracorporeal treatment of localised breast cancer.
Previous studies have shown that high intensity focused ultrasound (HIFU) ablation can trigger activation of host antitumor responses after direct tumor destruction.
The goal of this study was to investigate the status and functions of tumor-infiltrating antigen presenting cells (APCs) after HIFU ablation of human breast cancer, and to explore the mechanisms regarding HIFU-enhanced antitumor response.
Forty-eight women with biopsy-proven breast cancer were divided randomly into a control group (n = 25) and a HIFU group (n = 23). Patients in the control group received modified radical mastectomy, and those in the HIFU group underwent HIFU ablation of primary breast cancer, followed by modified radical mastectomy within 1–2 weeks. Using immunohistochemical analysis, tumor-infiltrating dendritic cells (DCs), macrophages, B lymphocytes and expression of HLA-DR and costimulatory molecules on DCs and macrophages were assessed in all patients.
The results showed that APCs infiltrated along the margins of the ablated regions in all HIFU-treated tumors, and numbers of tumor-infiltrating DCs, macrophages and B lymphocytes increased significantly in the HIFU group. Compared with the values in the control group, the percentage of DCs and macrophages expressing HLA-DR, CD80 and CD86 was significantly greater in the HIFU group. There were statistically significant differences between numbers of S-100+ HLA-DR+, S-100+ CD80+, S-100+ CD86+, CD68+ HLA-DR+, CD68+ CD80+ and CD68+ CD86+ cells in the control and HIFU groups, respectively.It was concluded that HIFU ablation induces significant infiltration of APCs within the residual tumor debris in patients with breast cancer, and most of the tumor-infiltrating DCs and macrophages were activated after HIFU ablation.